

ACHA Webinars Presents:

End of Life – Advance Care Planning in CHD

Wednesday, April 20, 2016, 7 p.m. – 8 p.m. EDT

**Presenter:
Ali N. Zaidi, MD**

About the Webinar

The landscape of congenital heart disease (CHD) care has changed and there are now more adults than children living with CHD. While a difficult conversation for patients and health providers, talking with your family and your ACHD healthcare team about End of Life (EOL) care is an important part of your healthcare planning. What does this mean? When is the right time? Who should initiate it? What is the difference between palliative care and hospice? Register today to learn about all of this, as well as what is meant by advance directives, living will, and power of attorney. You don't want to miss this webinar.



REGISTER NOW:

<https://attendee.gotowebinar.com/register/8236588212134610435>

About the Presenter

Ali Zaidi, MD, is an adult congenital heart disease (ACHD) cardiologist who trained in ACHD, pediatric cardiology and adult cardiovascular disease at the Ohio State University and Nationwide Children's Hospital in Columbus, OH.

He also has advanced training in cardiac imaging at The Ohio State University. He was the Director of ACHD Research at The Ohio State University and Nationwide Children's Hospital and is now the Director of the Montefiore Adult Congenital Heart Disease Program (MAAtCH) at the Montefiore Medical Center, Albert Einstein College of Medicine in New York.

About the Adult Congenital Heart Association

The mission of the Adult Congenital Heart Association (ACHA) is to improve and extend the lives of the millions born with heart defects through education, advocacy and the promotion of research. If you would like to find out more about our programming, visit our website, www.achaheart.org. To support ACHA's mission to improve and prolong the lives of heart defect survivors, you can make a donation on our website.

This webinar was made possible in part by unrestricted educational grants from Actelion Pharmaceuticals US, Inc. and Gilead Sciences.

